3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Neoplasms
4
Lung Neoplasms
4
Advanced Solid Tumors
3
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Thoracic Neoplasms
1
Solid Tumor, Adult
1
Solid Tumor
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Noonan Syndrome
1
Neoplasms by Site
1
Mesothelioma
1
Lung Diseases
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
1
Hereditary Sensory and Autonomic Neuropathies
1
Healthy Participants
1
Carcinoma
1
Bronchial Neoplasms
1
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
6
Proton Therapy
3
spartalizumab
2
Rosuvastatin Calcium
2
Paclitaxel
2
Immune Checkpoint Inhibitors
2
Cetuximab
2
toripalimab
1
sotorasib
1
peposertib
1
osimertinib
1
necitumumab
1
mirdametinib
1
leronlimab
1
apatinib
1
amivantamab
1
abemaciclib
1
Valganciclovir
1
Trastuzumab
1
Therapeutics
1
Rifampin
1
Radiotherapy
1
PankoMab-GEX
1
Panitumumab
1
Midazolam
1
Metformin
1
MEK inhibitor I
1
Jupiter
1
JPT1 protein, human
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Solid Tumor, Adult
×
sotorasib
×
Clear all
NCT04092673
2024-05-21
Zotatifin
Effector Therapeutics
Phase 1/2
Unknown
30 enrolled